Benitec Biopharma Inc.
For the period ended Jun 30, 2026. Filed Sep 14, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Sep 14, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| BENITEC BIOPHARMA INC. | |
|---|---|
| By: | /s/ Dr. Jerel Banks |
| Dr. Jerel Banks | |
| Chief Executive Officer | |
| Date: | September 14, 2026 |
|---|
POWER OF ATTORNEY
BY THESE PRESENTS, each person whose signature appears below constitutes and appoints Dr. Jerel Banks and Megan Boston his or her true and lawful attorney-in-fact and agents, with full power of substitution and resubstitution for him or her and in his or her name, place and stead, in any and all capacities to sign any and all amendments to this annual report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact or his or her substitute, each acting alone, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Dr. Jerel Banks | Chief Executive Officer, Chairman of the Board and | September 14, 2026 |
| Dr. Jerel Banks | Director (principal executive officer) | |
| /s/ Megan Boston | Chief Financial Officer | September 14, 2026 |
| Megan Boston | (principal accounting and financialofficer) | |
| /s/ J. Kevin Buchi | Director | September 14, 2026 |
| J. Kevin Buchi | ||
| /s/ Peter Francis | Director | September 14, 2026 |
| Peter Francis | ||
| /s/ Dr. David Friedman | Director | September 14, 2026 |
| Dr. David Friedman | ||
| /s/ Dr. Sharon Mates | Director | September 14, 2026 |
| Dr. Sharon Mates | ||
| /s/ Kishan (“Kishen”) Mehta | Director | September 14, 2026 |
| Kishan (“Kishen”) Mehta | ||
| /s/ Edward Smith | Director | September 14, 2026 |
| Edward Smith | ||
IV-5
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.